by Pulmonary edema refers to fluid accumulation in the air sacs (alveoli) and tissues of the lungs. The usual cause is heart failure, which causes elevated pressures in the blood vessels of the lungs, allowing fluid from the capillaries to leak into the lung tissues and air spaces. Other potential causes include hypoxic injury, near drowning, and certain medications among others. Pulmonary edema is usually treated by addressing its underlying causes and managing symptoms. Medications that help manage fluid overload, reduce pressure, or improve oxygenation are commonly used. Treatments may also include bronchodilators to help open airways and supplemental oxygen therapy.
The global pulmonary edema therapeutics market is estimated to be valued at US$ 13990.01 Bn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2024 to 2031.
Market Dynamics:
Rising Prevalence of Respiratory Disorders: The rising prevalence of respiratory disorders such as asthma, COPD, pulmonary fibrosis and others is one of the major factors enhancing the demand for pulmonary edema therapeutics. As per a study published by the British Lung Foundation, over 5.4 million people in the UK suffer from COPD. Additionally, the growing geriatric population which is more prone to develop respiratory disorders will further propel the market growth over the coming years.
Technological Advancements: Continuous research and development activities have led to introduction of novel and efficient treatment options for pulmonary edema. For instance, in March 2022, DarioHealth Corp. launched its Dario Breathing Solution, a non-invasive pulmonary edema monitoring system, to help diagnose and manage pulmonary or peripheral edema at an early stage. Development of such innovative products will augment the pulmonary edema therapeutics industry expansion during the forecast period.
SWOT Analysis
Strength: Pulmonary edema therapeutics market offer a wide range of drugs for the treatment of pulmonary edema such as loop diuretics, cardiac glycosides, and vasodilators. These drugs are highly effective in reducing fluid buildup in lungs and alleviating associated symptoms. Rise in prevalence ofcardiovascular and lung diseases have increased the demand for various pulmonary edema treatment options.
Weakness: Side effects associated with certain pulmonary edema drugs such as electrolyte imbalance, ototoxicity, and arrhythmias may limit their use especially in critically ill patients. High treatment cost of biologics and therapeutics also adversely impact market growth.
Opportunity: Increasing research activities focused on development of novel targeted therapies and combination drug regimens present lucrative opportunities. Also, growing healthcare expenditures in emerging nations will support market expansion over the coming years.
Threats: Stiff competition among established and local players is a major challenge. Stringent regulatory approvals for new therapies increase risk of delay in product commercialization.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market Demand is expected to witness high growth. The market size is projected to reach US$ 13990.01 Bn by 2031, registering a CAGR of 9.8% over the forecast period of 2024 to 2031.
Regional analysis:
North America region currently dominates the market and is expected to maintain its leading position during the forecast period. Higher prevalence of cardiovascular and lung diseases along with advanced healthcare infrastructure are primary factors fueling regional market growth. Asia Pacific market is projected to showcase fastest growth due to improvements in medical facilities, rapid economic development and rising healthcare spending in major Asian countries.
Key players:
Key players operating in the Pulmonary Edema Therapeutics market are Knoll Inc., Freudenberg Group, Avgol Ltd., Carnegie Fabrics LLC, Eximius Incorporation, Berry Global Group Inc., Asahi Kasei Corporation, Ahlstrom Munksjo OYJ, Kimberly-Clark Corporation, and Paramount Tech Fab Industries, among others. These companies are focusing on new product launches, collaborations and geographical expansion strategies to consolidate their market shares.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
